Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials
2023 · Nature Medicine · 348 citations
https://doi.org/10.1038/s41591-022-02103-8
V
Vivek Subbiah
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
1.4K
Papers
31.1K
Citations
78
h-index
392
i10-index
Vivek Subbiah is an academic researcher. The author has contributed to research in topics: Cancer Genomics and Diagnostics & Lung Cancer Treatments and Mutations & Sarcoma Diagnosis and Treatment. The author has an h-index of 78, co-authored 1216 publications.
ORCID: 0000-0002-6064-6837Papers by this author
worksClinical Development of BRAF plus MEK Inhibitor Combinations
2020 · Trends in cancer · 327 citations
https://doi.org/10.1016/j.trecan.2020.05.009
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
2023 · Nature Medicine · 268 citations
https://doi.org/10.1038/s41591-023-02321-8
Pan-cancer efficacy of pralsetinib in patients with RET fusion–positive solid tumors from the phase 1/2 ARROW trial
2022 · Nature Medicine · 224 citations
https://doi.org/10.1038/s41591-022-01931-y
EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment
2021 · Nature Reviews Clinical Oncology · 190 citations
https://doi.org/10.1038/s41571-021-00558-1
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
2019 · Journal for ImmunoTherapy of Cancer · 152 citations
https://doi.org/10.1186/s40425-019-0722-x
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat